The Uni-flo2 offers users much more freedom of movement than a dual prong cannula. Many hardly know they are wearing a cannula.
The development of the Uni-flo2 nasal cannula began as a quest by two of our founders, Dr. Hugh Payton and Mr. Campbell Cauthen.
They wanted to eliminate the problems they’d seen over many years of treating patients with respiratory diseases. Dr. Payton had retired from a 50-year practice in rural Ohio and Mr. Cauthen had worked as a Registered Respiratory Therapist for more than 30 years, treating patients who needed supplemental oxygen.
In their practices, they identified multiple problems with existing oxygen cannula devices. Numerous problems had not been addressed in any significant manner since the introduction of the dual prong cannula 68 years ago. Considering the aging population and the increase in chronic obstructive pulmonary disease (COPD), Dr. Payton and Mr. Cauthen decided that now was the time to solve the dual cannula problems and improve the health of tens of thousands of patients needing supplemental oxygen while also increasing their self-esteem.
Three partners, Dr. Payton, Mr. Cauthen, and Mrs. Deborah Chadbourne, launched UPODS, LLC (unilateral patient oxygen delivery system) in 2013. US Patents for their invention were granted in September 2016 and March 2018. These innovations represent the first substantive improvement in the delivery of low flow oxygen via nasal cannula in decades. FDA facility registration was secured in 2016 and manufacturing and distribution capability for the Uni-flo2 was also achieved during 2016. Verification of HCPCS code A4615 was obtained in April 2018. UPODS is proud to offer the superior Uni-flo2 to patients, clinicians, and health care practitioners.